PFE vs SBUX: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and Starbucks Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction
Grade B+
VS
Starbucks Corporation · Consumer Cyclical
$96.60
+19.0% upside to fair value
Med Conviction
Grade B+
QuantHub Verdict
PFE has more upside to fair value
(+30.1%).
PFE trades at a lower forward P/E
(9.5x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
SBUX |
| Current Price |
$26.91 |
$96.60 |
| Fair Value Estimate |
$35.00 |
$115.00 |
| Upside to Fair Value |
+30.1%
|
+19.0%
|
| Market Cap |
$153.0B |
$110.1B |
| Forward P/E |
9.5x
|
42.2x
|
| EV / EBITDA |
13.8x
|
22.5x
|
| Price / Sales |
2.4x
|
3.0x
|
| Price / FCF |
16.8x
|
45.1x
|
| Revenue Growth YoY |
-1.6%
|
+2.8%
|
| Gross Margin |
70.3%
|
24.2%
|
| Operating Margin |
24.7%
|
9.6%
|
| Return on Equity |
9.0%
|
-22.9%
|
| Dividend Yield |
6.4% |
2.55% |
| FCF Yield |
5.9%
|
2.2%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Starbucks is the world's largest specialty coffee retailer with over 39,000 stores across 86 markets, generating $37.2B in annual revenue. Under CEO Brian Niccol, now 19 months into his tenure after joining from Chipotle in September 2024, the company is executing the Back to Starbucks operational turnaround focused on service speed, menu simplification, and store experience reinvention. At P/S 2…
Accumulation Zones
| Metric |
PFE |
SBUX |
| Zone Low |
$25.00 |
$88.00 |
| Zone High |
$29.00 |
$98.00 |
| In Buy Zone? |
Yes
|
Yes
|